Myeloproliferative neoplasm other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myeloproliferative disease}}
{{Myeloproliferative disease}}
{{CMG}} {{AE}} {{MJK}}
{{CMG}} {{AE}} {{MJK}} {{shyam}}
==Overview==
==Overview==
Other diagnostic studies for myeloproliferative neoplasm include [[bone marrow aspiration]] and [[biopsy|trephine biopsy]], [[lumbar puncture]], and [[lymph node biopsy]].
Other diagnostic studies for myeloproliferative neoplasm include [[bone marrow aspiration]] and [[biopsy|trephine biopsy]], [[erythropoietin]] level, [[lumbar puncture]], and [[lymph node biopsy]].


==Other diagnostic studies==
==Other diagnostic studies==
Other diagnostic studies for myeloproliferative neoplasm include:<ref name="cancer.ca">Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab</ref><ref>{{cite book |author=Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates|title=Dacie & Lewis Practical Haematology |publisher=W B Saunders |location=London |year= |pages= |isbn=0-443-06377-X |pages=586}}</ref>
Other diagnostic studies for myeloproliferative neoplasm include:<ref name="cancer.ca">Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab</ref><ref>{{cite book |author=Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates|title=Dacie & Lewis Practical Haematology |publisher=W B Saunders |location=London |year= |pages= |isbn=0-443-06377-X |pages=586}}</ref>
*[[Bone marrow aspiration]] and [[biopsy|trephine biopsy]]: This is an invasive diagnostic procedure that is sometimes required for the diagnosis of myeloproliferative neoplasm. Bone marrow biopsy usually shows high proportions of [[leukocytes]], [[erythrocytes]], and [[thrombocytes]]. This is referred to as [[panmyelosis]]. These findings on a bone marrow biopsy constitute one of the major diagnostic criteria for various subtypes of myeloproliferative neoplasm in the 2016 WHO classification.<ref name="pmid27069254">{{cite journal| author=Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al.| title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. | journal=Blood | year= 2016 | volume= 127 | issue= 20 | pages= 2391-405 | pmid=27069254 | doi=10.1182/blood-2016-03-643544 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27069254  }} </ref>
*[[Bone marrow aspiration]] and [[biopsy|trephine biopsy]]: This is an invasive diagnostic procedure that is sometimes required for the diagnosis of myeloproliferative neoplasm. Bone marrow biopsy usually shows high proportions of [[leukocytes]], [[erythrocytes]], and [[thrombocytes]]. This is referred to as [[panmyelosis]] or [[hypercellularity]]. Cellularity normally decreases with age, but the cellularity will relatively high in patients with myeloproliferative neoplasm. The findings on a bone marrow biopsy constitute one of the major diagnostic criteria for various subtypes of myeloproliferative neoplasm in the 2016 WHO classification.<ref name="pmid27069254">{{cite journal| author=Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al.| title=The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. | journal=Blood | year= 2016 | volume= 127 | issue= 20 | pages= 2391-405 | pmid=27069254 | doi=10.1182/blood-2016-03-643544 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27069254  }} </ref>
*[[Erythropoietin]] level: [[Erythropoietin]] level is usually low in polycythemia vera, one of the subtypes of myeloproliferative neoplasm. This is because polycythemia vera is characterized by autonomous production of [[red blood cells]] in an erythropoietin-independent manner.
*[[Erythropoietin]] level: [[Erythropoietin]] level is usually low in [[polycythemia vera]], one of the subtypes of myeloproliferative neoplasm. This is because polycythemia vera is characterized by autonomous production of [[red blood cells]] in an erythropoietin-independent manner.
*[[Lumbar puncture]]
*[[Lumbar puncture]]: This is used to detect any metastasis to the [[cerebral spinal fluid]] (CSF), which is rare.
:*Used to detect any metastasis to the [[cerebral spinal fluid]] (CSF)
*[[Lymph node biopsy]]: This is used to obtain a diagnostic specimen, or to detect and/or determine the type of leukemic cells if leukemia is present.
*[[Lymph node biopsy]]
:*Used to detect and/or determine the type of leukemic cells
*[[Carboxyhaemoglobin]] level
*[[Arterial oxygen saturation]]


==Gallery==
==Gallery==

Latest revision as of 15:51, 28 June 2018

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm other diagnostic studies

on Myeloproliferative neoplasm other diagnostic studies

Myeloproliferative neoplasm other diagnostic studies in the news

Blogs on Myeloproliferative neoplasm other diagnostic studies

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

Other diagnostic studies for myeloproliferative neoplasm include bone marrow aspiration and trephine biopsy, erythropoietin level, lumbar puncture, and lymph node biopsy.

Other diagnostic studies

Other diagnostic studies for myeloproliferative neoplasm include:[1][2]

  • Bone marrow aspiration and trephine biopsy: This is an invasive diagnostic procedure that is sometimes required for the diagnosis of myeloproliferative neoplasm. Bone marrow biopsy usually shows high proportions of leukocytes, erythrocytes, and thrombocytes. This is referred to as panmyelosis or hypercellularity. Cellularity normally decreases with age, but the cellularity will relatively high in patients with myeloproliferative neoplasm. The findings on a bone marrow biopsy constitute one of the major diagnostic criteria for various subtypes of myeloproliferative neoplasm in the 2016 WHO classification.[3]
  • Erythropoietin level: Erythropoietin level is usually low in polycythemia vera, one of the subtypes of myeloproliferative neoplasm. This is because polycythemia vera is characterized by autonomous production of red blood cells in an erythropoietin-independent manner.
  • Lumbar puncture: This is used to detect any metastasis to the cerebral spinal fluid (CSF), which is rare.
  • Lymph node biopsy: This is used to obtain a diagnostic specimen, or to detect and/or determine the type of leukemic cells if leukemia is present.

Gallery

References

  1. Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab
  2. Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates. Dacie & Lewis Practical Haematology. London: W B Saunders. p. 586. ISBN 0-443-06377-X.
  3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM; et al. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–405. doi:10.1182/blood-2016-03-643544. PMID 27069254.
  4. 4.0 4.1 National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq

Template:WH Template:WS